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Abstract  
 
We report the discovery that flow and Svep1 are modulator of vessel anastomosis 
during developmental angiogenesis in zebrafish embryos. We show that loss of Svep1 
and blood flow reduction both contribute to defective anastomosis of intersegmental 
vessels. We show that this defect in primary angiogenic sprouts is associated with an 
expansion of Apelin-positive tip cells and with reduced formation and lumenisation of 
the dorsal longitudinal anastomotic vessel. Mechanistically, our results suggest that 
flow and Svep1 act synergistically to modulate vascular network formation in the 
zebrafish trunk.   
 
Non-standards Abbreviations and Acronyms 
DLAV: dorsal longitudinal anastomotic vessel 
hpf: hours post-fertilization 
ISVs: intersegmental vessels 
DA: Dorsal Aorta 
PCV: Posterior Cardinal Vein 
VEGFR-2: vascular endothelial growth factor receptor-2 
Kdr; Kinase insert domain receptor 
Kdrl: Kinase insert domain receptor like 
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Angiogenesis defines the formation of new vessels from pre-existing ones and is a 
stepwise process that leads to the formation of a perfused network of arteries and veins 
that are optimally organised to serve the metabolic needs of the developing embryo. 
In zebrafish embryos, vasculogenesis results in the formation of the two main blood 
vessels, namely the dorsal aorta (DA) and the posterior cardinal vein (PCV). Later, 
angiogenic sprouts emerge from the DA. These multicellular sprouts are composed of 
a leading tip cell followed by stalk cells [1], and migrate dorsally in between the vertical 
somite boundaries to form intersegmental vessels (ISVs)[2]. The proliferation and 
migration of ISVs to the dorsal part of the embryo is driven by Vegfa signalling, through 
binding to the VEGFR2 zebrafish ortholog Kdr and its ohnolog Kdrl [3-8]. Activation of 
Kdrl signalling in the leading ISV endothelial cell (tip), mediated in large part via 
downstream phosphorylation of the serine/threonine kinase ERK1/2, promotes 
migratory behaviour. In parallel, activation of Kdrl signalling in the tip cell leads to Notch 
mediated inhibition of Kdrl signalling in trailing cells (stalks), preventing their 
conversion into tip cells and promoting their proliferation to support ISV expansion [6, 
9, 10]. Around 30-32 hours post-fertilisation (hpf), the leading tip cells of the ISVs start 
to anastomose with their ipsilateral neighbours, a process that ultimately leads to the 
formation of the dorsal longitudinal anastomotic vessel (DLAV), dorsal to the neural 
tube [11, 12]. The DLAV is initially a paired bilateral structure that is fully lumenised by 
48 hpf, but subsequently both sides progressively connect to form a complex plexus 
[2, 12]. Zygmunt and colleagues demonstrated that maturation of the DLAV plexus is 
regulated by flow and Vegfr signalling after 48 hpf. However, while they show that flow 
is dispensable for the initial formation of the DLAV, little is known about the cellular 
mechanism driving the anastomosis of ipsilateral ISVs and the lumenisation of the 
DLAV segments during DLAV formation (32 to 48 hpf).  
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Recent reports have characterised the importance of svep1/polydom, a secreted ECM 
protein that has been reported to mediate cell-to-substrate adhesion in vitro, in an 
integrin 91-dependent manner [13], as a regulator of secondary angiogenesis [14, 
15]. In zebrafish, loss of function svep1 mutants exhibit a reduced number of venous 
and lymphatic precursor (parachordal lymphangioblasts, PLs) emerging from the PCV 
during secondary angiogenesis (from 32 hpf). In addition, PLs show reduced migration 
capacity from the horizontal myoseptum. Both these defects lead to an increased 
number of arterial ISVs (aISVs) and a severe reduction in lymphatic trunk vasculature. 
Here, we uncover a completely new and distinct role for Svep1 in the regulation of 
DLAV formation under reduced flow conditions, acting in part through modulation of 
Vegfa/Vegfr signalling in endothelial cells.   
 
Material and Methods 
 
Zebrafish husbandry and transgenic lines 
Zebrafish (Danio rerio) were raised and staged as previously described [16]. The 
following transgenic lines were used: Tg[fli1a:EGFP]y1 [17] (labeling all endothelial 
cells),  Tg[gata1a:dsRed]sd2 [18] (labeling all erythrocytes), Tg[-0.8flt1:RFP]hu5333 [5] 
(strongly labels arterial endothelial cells), TgBAC(apln:eGFP)bns157 [19] (labeling 
endothelial tip cells). Tg(svep1:Gal4FF;UAS:GFP) (labeling svep1 positive cells) [14]. 
The svep1hu512+/- line has been described previously [14]. For growing and breeding of 
transgenic lines we comply with regulations of the ethical commission animal science 
of MDC Berlin and with FELASA guidelines [20].  
 
Tricaine treatment 
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To slow down heart rate and blood flow during DLAV formation, embryos were treated 
with 0.007%, 0.014% (1X) or 0.028% (2X) tricaine (MS-222, Sigma) between 30 and 
48 hpf, as indicated in the figure legends.  
 
Morpholino knockdown 
Morpholinos against svep1 (5ng) and flt1 (1ng) were used as previously described in 
[15, 21] and injected in the yolk of zebrafish embryos at the one-cell stage.  
 
Statistical Analysis 
All quantifications were performed in the trunk region of zebrafish embryos, across 7-
9 somites. (N) refers to experimental replicates, (n) refers to number of embryos. 
Statistical analysis was performed with Mann-Whitney-U tests, unless indicated 
otherwise. No statistical method was used to predetermine sample size. Data 
represent mean ± standard deviation of representative experiments (except when 
indicated otherwise). Statistical tests were conducted using Prism (GraphPad) 
software. Adequate tests were chosen according to the data to fulfil test assumptions. 
Sample sizes, number of repeat experiments, performed tests and p-values are 
indicated per experiment.  
 
Zebrafish embryos were selected based on the following pre-established criteria: 
normal morphology, beating heart, presence of circulating red blood cells. The 
experiments were not randomized. For every experiment treated and control embryos 
were derived from the same egg lay. The investigators were not blinded to allocation 
during experiments and outcome assessment. 
 
Live imaging 
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Embryos were anaesthetized in 0.014% tricaine (MS-222, Sigma), mounted in a 35 
mm glass bottom petri dish (0.17 mm, MatTek) using 0.6-1% reduced melting point 
agarose (Sigma) containing 0.014% tricaine, and bathed in E3 media containing 
0.014% (1X tricaine) and 0.003% PTU. Time-lapse imaging was performed using an 
upright 3i spinning-disc confocal using a Zeiss Plan-Apochromat, 20x, 40x/1.0 NA 
water-dipping objective. Image processing was performed using Fiji software [22]. 
 
Isolation of endothelial cells  
48 hpf Tg[fli1a: nEGFP]y7 and Tg[fli1a: EGFP]y1 crossed to Tg[gata1:dsRed] embryos 
were dechorionated using a solution of 1mg/mL Pronase (Sigma Aldrich) on an orbital 
shaker for 10 minutes at room temperatures. Up to 250 dechorionated embryos per 
conditions were anaesthetized with 1X (0.014%) tricaine and transferred to a 1.5 mL 
Eppendorf with 1 mL calcium-free Ringer solution (116 mM NaCL, 2.9 mM KCL, 5 mM 
HEPES pH7.2) to remove the yolks. After pipetting gently up and down with a 1mL tip 
the embryos were centrifugated at 2000 rpm for 5 minutes at 4°C. The supernatant 
was removed, and the procedure repeated until all the yolks were removed and the 
solution clear. The calcium-free ringer solution was replaced with 1 mL of protease 
solution (72 g/mL Liberase DH research grade from Merck/Sigma, 0.4U/mL DNaseI-
Invitrogen). The embryos were incubated at 28.5C on an orbital shaker for 20 minutes, 
pipetting up and down with a 200L tip every 3 minutes, to form a homogenous solution 
of cells. The dissociation process was stopped by placing the embryos on ice and 
adding 2L CaCl2 and 0.5 L FBS per mL. The cell suspension was centrifuged for at 
2000 rpm for 5 minutes at 4°C. The supernatant was discarded, and the cells 
resuspended in sorting solution (2mM EDTA, 0.4U/mL DNaseI, 0.5% FBS in DPBS). 
The solution was passed through a 40m strainer inside a 50 mL falcon tube, 
previously washed with 500L sorting solution. Following filtration, 500L sorting 
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solution was added to the strainer. The filtered solution was centrifuged at 2000 RPM 
for 5 minutes at 4C. The supernatant was removed, and the cell resuspended in 700 
L sorting solution. The cell suspension was then loaded onto an ARIA III FACsorter 
(BD Bioscience). Using Tg[gata1:dsRED] only embryos for gating, we specifically 
sorted GFP+, dsRED- cells to remove red blood cells with fli1a promoter activation at 
this specific developmental stage. Upon centrifugation and removal of the supernatant, 
all cells were stored immediately at -80C until protein extraction.  
 
Protein extraction 
Sorted embryos were treated with 40L Lysis Buffer (1mL 1M Tris-HCl, 0.4 mL 0.5M 
EDTA, 8.75 mL 10% Brij 96, 1.25 mL 10% NP-40 to 100mL with dH2O) and 0.4L 
Protease Inhibitor cocktail (ThermoFischer). The samples were homogenized with a 
pestle and centrifuged at 13000 RPM for 15 minutes at 4C. The protein supernatant 




20-50g of the protein lysates (equal amount for each condition to compare) were 
diluted in 18.7L water and 6.3L loading buffer (25L total volume) and heated for 5 
min at 95°C to denature proteins. The samples were loaded and run alongside a 10l 
ladder marker (Novex Sharp Pre-Stained - thermoFischer) for 1h at 150V and 
subsequently transferred onto previously MeOH activated polyvinylidene fluoride 
membranes. Membranes were blocked with 5% non-fat dry milk in 50 mg/mL TBS-T 
for 1.5h at room temperature and then incubated with primary antibody against p-ERK, 
overnight at 4°C (1:250, (Erk1/2) (Thr202/Tyr204) #9101, Cell Signaling Technology). 
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After incubation with primary antibody, the membranes were washed 4 times in 50 
mg/mL TBS-T and then incubated with secondary antibodies (1:4000 anti-rabbit) and 
washed 3 times with 50 mg/mLTBS-T. Immunodetection was performed using a 
chemiluminescence kit (1mL SuperSignal West Dura; Pierce), and bands were 
developed using the Las-4000 imaging system. After initial immunodetection, 
membranes were stripped of antibodies by using the Stripping kit (ThermoFisher) at 
56°C for 40min and re-probed with anti–GFP antibody for 1h (1:1000, Origene 
R1091P). Band intensity was measured using the histogram function on the Fiji 
software, with control and treated samples on the same blot [22].   
 
Blood flow and heart rate measurements  
Embryos were anaesthetized and imaged on an upright 3i spinning-disc confocal using 
a Zeiss Plan-Apochromat, 20x/1.0 NA water-dipping objective with a frame interval of 
10ms. Kymographs were generated using the MultipleKymograph plugin in ImageJ to 
quantify heart rate over an 8 second period, synced to the beginning of a heartbeat 
(line width: 1).  
 
To estimate instantaneous blood flow speed, we cropped images of the dorsal aorta 
and measured average frame-to-frame translation of red blood cells using the Kuglin-
Hines algorithm (Kuglin and Hines, 1975) for image phase-correlation. In brief, the 
phase correlation map between two adjacent frames was calculated by multiplying the 
Fast Fourier transform (FFt) of framei and a conjugate FFt of framei+1. The inverse FFt 
of the phase correlation provides a correlation map with a peak offset from the center 
by the relative shift between the frames. The position of the peak was determined by 
finding the local maximum in a Gaussian filtered correlation map. The velocity data 
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was smoothed with a moving average filter with a span of 5 frames. Analysis was 
performed in Matlab (Mathworks, Inc.).  
 
Chemical treatment 
Where indicated, embryos were treated with VEGFR inhibitors ZM323881 (Tocris 
Bioscience) or SU5416 (sigma Aldrich), from 30 to 48hpf, in addition to 0.003% PTU 
















svep1 mutant and morphant zebrafish embryos exhibit vascular anastomosis 
defects.  
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Imaging angiogenesis in the trunk of svep1 loss-of-function mutants (Ly02-12 – named 
svep1hu4767 in this manuscript) [14] from 30 to 48 hpf, we noticed that a significant 
number of primary angiogenic sprouts failed to anastomose with their ipsilateral 
neighbours (Figure 1A) (Supplementary Video 1, 2). In the majority of cases (74%  
33), the DLAV gaps arise following the regression of a pre-existing connection between 
ipsilateral neighbouring ISVs, rather than an absence of connection (N=6 experiments, 
n=18 mutants). Additionally, only a minority of these connections (13%, N=6 
experiments, n=17 mutants) were transiently lumenised before regressing. These 
results suggest that in this context, svep1 loss of function negatively affects the 
stabilisation of vascular connections between neighbouring sprouts.  
 
We quantified the number of gaps in the DLAV, and lumenisation status of existing 
DLAV segments at 48 hpf, a time at which the DLAV is considered fully formed and 
almost fully lumenised in wild type (WT) zebrafish embryos [2, 12]. svep1512 mutants 
exhibited a significantly increased number of gaps in their DLAV at 48 hpf (25.5%  
23.4 versus 2.6%  5.6 in their WT siblings) and a significant decrease of lumenised 
DLAV segments (47.8 %  33.1 versus 86.4 %  17.3) (Figure 1B-D). These 
phenotypes were also observed in svep1 morphants compared to control morphants 
(DLAV gaps: 36.3%  25.4 versus 6%  10.9; lumenised DLAV segments: 46.1%  
33.8 versus 94.7  10.5) (Figure 1E, F). In addition, while the expressivity of the 
morphant phenotype in different zebrafish transgenic lines and clutches varied 
markedly, we observed a statistically significant difference between svep1 and control 
morphants in all cases, (Supplementary Figure 1). 
 
svep1 loss-of-function sensitises angiogenic remodelling to reduced blood flow. 
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Surprisingly, we could not detect any anastomosis defects at the DLAV in svep1512 
mutants and morphants when imaged at 2 dpf, whilst they continued to exhibit the 
previously reported PL phenotypes [14] (PLs at the horizontal myoseptum: 47.6%  
17.5 versus 80.2%  19.4% in WT clutch mates and aISVs: 65.4%  15.1 versus 49.3% 
 15 in WT siblings, N=4, n=12 mutants, n=25 WT)). The DLAV phenotypes instead 
only occurred in mutant embryos that were live imaged from 30 to 48 hpf. Upon closer 
inspection, we found that treatment with tricaine (tricaine mesylate – MS222), a muscle 
relaxant commonly used to immobilise zebrafish embryos, lead to a dose-dependent 
emergence of the DLAV phenotypes in svep1 loss-of-function morphants (Figure 2A, 
B) following treatment with concentration of 1X (0.014%) or above from 30 to 48 hpf.  
In addition, removal of tricaine from mutant embryos lead to a significant recovery of 
the DLAV vasculature at 72 hpf, with only 27% ( 26) of the DLAV gaps still present at 
that stage (supplementary Figure 2A, B).  
 
Previous work revealed that svep1 loss of function is associated with cardiac defects 
[23]. To test if svep1 loss-of-function augments tricaine-induced blood flow reduction, 
we quantified heartbeats per minutes in control and svep1 morphants and found no 
differences in embryos treated with 1X (0.014%) or 2X (0.028%) tricaine from 30 to 48 
hpf (supplementary Figure 2C). However, we found the mean blood flow speed to be 
significantly decreased in svep1 morphants compared to control morphants when 
treated with 1X tricaine (MO-CTL 5ng: 679um/s ± 205, MO-svep1 5ng: 521 um/s ± 
190). This suggests that the cardiac phenotype reported in svep1 loss-of-function 
embryos exacerbates the blood flow reduction induced by tricaine treatment.  
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To further characterize the phenotype, we therefore decided to begin our investigation 
at 30 hpf, as this time point marks the beginning of ISV ipsilateral anastomosis in most 
embryos (Figure 1A).  As tricaine treatment leads to a reduction of blood flow speed 
[24], we investigated whether a general blood flow speed reduction or a reduction of 
erythrocytes-dependent shear stress is responsible for the DLAV phenotype in svep1 
morphants. In the absence of tricaine treatment, simultaneous inhibition of svep1 
function and erythrocyte formation, using svep1 and gata1 morpholinos, did not lead 
to any DLAV phenotypes (Figure 2C, D), suggesting that shear stress does not 
modulate DLAV formation at that developmental stage. However, in the absence of 
tricaine treatment, complete abolition of blood flow using the tnnt2a morpholino lead to 
a DLAV phenotype in svep1 morphants (Figure 2E, F) (16.4%  16.2 versus 3.5  6.2 
in svep1 morphants only). Abolition of blood flow in svep1 homozygous mutants further 
increases the proportion of fish exhibiting a strong DLAV phenotype (30% compared 
to 5.3% of WT clutch mate) (Supplementary Figure 2F).   These results suggest that 
while svep1 loss-of-function produces a cardiac defect that enhances the effect of 
tricaine on reducing blood flow, svep1 has an additive effect in modulating blood 
vessels anastomosis.  
 
Finally, we observed that svep1 loss of function significantly increases the percentage 
of short ISVs in tnn2a morphants at 48 hpf (14.6%  10.5 versus 4.8%  7.6 in tnnt2a 
morphants only). This led us to investigate the importance of svep1 in the regulation 
of angiogenic sprout identity and behaviour under reduced flow conditions.  
 
Svep1 is expressed in neurons of the neural tube and its expression is flow 
dependent 
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Imaging of the svep1 reporter line Tg(svep1: Gal4FF;UAS:GFP) at 48 hpf showed 
strong GFP expression in dorsal epithelial cells, above the neural tube, and in 
individual neurons of the neural tube (Figure 3A, Supplementary Figure 3A, B). 
Treatment with 1X tricaine from 30 to 48 hpf led to a significant reduction in svep1 
expression throughout the trunk area, particularly in the neural tube at 48 hpf (Figure 
3B). In addition, tricaine treatment between 30 and 48 hpf lead to a significant reduction 
in svep1 endogenous expression within the neural tube and ventral somite boundary 
(supplementary Figure 3C), suggesting that blood flow not only sensitises angiogenic 
sprouts to svep1 downregulation but also directly affects svep1 expression. 
 
svep1 loss-of-function leads to a defect in tip/stalk cell specification in primary 
angiogenic sprouts.  
 
The formation of the DLAV is initiated by the anastomosis of ipsilateral arterial sprouts, 
led by a tip cell [1]. To investigate tip cell identity in the zebrafish trunk, we took 
advantage of the recently published Tg(apln:eGFP) [19] reporter line, in which the 
nucleus of endothelial tip cells is highlighted by eGFP expression at 48 hpf. Following 
treatment with tricaine from 30 to 48 hpf, svep1 morphants exhibited an expansion of 
Apln positive endothelial cells in intersegmental vessels (ISVs), while control 
morphants predominantly presented Apln positive cells in the dorsal-most region of the 
vasculature, consistent with a contribution of tip cells to the formation of the DLAV 
(Figure 3C-F). In addition, svep1 morphants presented with an overall increase in Apln 
positive cells per ISVs (56.5%  24 versus 17.8%  13.3 in control morphants)(Figure 
3G).  
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As tip cell identity is in part characterised by increased levels of p-ERK downstream of 
Vegfa/Vegfr signalling, we next investigated this pathway activation in svep1 
morphants. Interestingly, sorted endothelial cells from 48 hpf svep1 morphants treated 
with 1X tricaine from 30 hpf, did not show a significant increase in p-ERK levels 
normalised to total ERK levels (Figure 3H, I). Overall, these results suggest that the 
DLAV phenotype present in svep1 morphants treated with tricaine is associated with 
a defect in tip/stalk cell specification in primary angiogenic sprouts. 
 
To test whether the observed expansion of tip cell specification is caused by the 
augmented reduction in blood flow speed observed in svep1 loss-of-function embryos, 
we investigated tip cell identity in control embryos treated with 2X tricaine compared 
to 1X tricaine. 2X tricaine treatment alone results in an exacerbated blood flow 
reduction to that observed in svep1 loss-of-function embryos treated with 1X tricaine 
(451 um/s ± 231.6, as presented by our laboratory in a recent manuscript [24], versus 
521 um/s ± 190). However, treatment with 2X tricaine of Apln-GFP embryos did not 
cause expansion of tip cell specification (Figure 3J, K), suggesting that this phenotype 
is primarily a consequence of svep1 loss-of-function under reduced flow condition.  
 
svep1 loss-of-function and knockdown are rescued by flt1 knockdown.  
 
To investigate whether the tip cell phenotype is mediated by, or dependent on, 
increased Vegfa/Vegfr signaling in svep1 morphants, we decided to modulate it in vivo, 
first by targeting Flt1 expression. In mice and zebrafish, Flt1 mainly functions as a 
decoy receptor with high affinity for Vegfa during development to modulate the 
activation of the Vegfa/Vegfr signalling pathway [21, 25, 26]. Alternative splicing of flt1 
generates two isoforms: a membrane bound form (mFlt1), and a soluble form (sflt1, an 
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alternative spliced and secreted form of mFlt1) [27]. Reports have shown that sFlt1 
acts as a negative regulator of tip cell formation in the zebrafish trunk [28]. 
 
To reduce flt1 expression, we used a morpholino targeting both mFlt1 and sFlt1 
expression. Similar to previous observations [21], flt1 morphants do not exhibit any 
DLAV defects at 48 hpf when treated with tricaine from 30 to 48 hpf. However, in svep1 
mutants and morphants, knockdown of flt1 expression lead to a rescue of DLAV 
formation defects (Figure 4A, B). Interestingly, flt1 knockdown rescued the DLAV 
segment lumenisation phenotype only in svep1 morphants but not in mutant embryos 
(Figure 4C, D), suggesting potential differences in the expressivity of the flt1 
knockdown in svep1 mutant and morphants.  
 
In addition to the DLAV rescue, flt1/svep1 double knockdown led to the formation of 
aberrant arterial loops in aISVs (18.5 %  12.4 versus 0.8%  2.7 in MO-svep1 and 
3.6%  6.1 in MO-flt1 only) (Figure 4E, F). The majority of these arterial loops were 
lumenised and composed of more than one endothelial cell (>1 cell/loop: 94.1% in 
n=34 loops). In 9.3% of somites (26/280), we also observed abnormal aISVs to aISVs 
connections (Figure 4H), which were never seen in control embryos. Thus, the rescue 
of connectivity at the DLAV level through flt1 knockdown was accompanied by an 
excess connectivity at aberrant locations. 
 
Importantly, flt1 morphants treated with 2X tricaine from 30-48 hpf exhibited aberrant 
arterial loops in only 2.4%  4.1 aISVs, while control morphants under the same 
treatment never exhibited any (N=3, n=21 MO-flt1 1ng, n=24 MO-CTL 1ng). In both 
conditions, we could not find abnormal aISVs to aISVs connections. These results 
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suggest that svep1 loss-of-function, rather than reduced blood flow, is the principal 
driver for the excess connectivity observed with concomitant flt1 knockdown.    
 
In search for the underlying cause of this hyperconnectivity, we investigated tip cell 
specification using the Apln-GFP transgenic reporter line. In embryos treated with 1X 
tricaine from 30 to 48hpf, flt1 knockdown led to an expansion and increase of the total 
number of Apln+ endothelial cells in aISVs, despite no significant DLAV formation 
defects (Figure 4I-K). svep1/flt1 double morphants exhibit significantly more Apln+ 
endothelial cells in the dorsal and ventral part of aISVs, and more Apln+ cells per aISV 
than both svep1 and flt1 morphants alone (more than one Apln+ cell in 87.6%  13.9 
ISVs versus 70.3%   17.7 in svep1 only morphants and 63.9   21.9 in flt1 only 
morphants)(Figure 1L).  
 
These results suggest that the expansion of the number of tip cells in aISVs per se is 
not the driver of anastomosis defects. 
 
Vegfa/Vegfr signalling is necessary for ISV lumenisation maintenance and DLAV 
formation 
 
Vegfa/Vegfr signalling regulates primary angiogenic sprouting in the developing 
zebrafish trunk. Inhibition of Vegfr tyrosine kinase activation between 18 and 20 hpf 
results in the absence of angiogenic sprouting from the dorsal aorta [29]. However, to 
our knowledge, there exist no reports for the role of active Vegfa/Vegfr signalling in the 
initial formation and lumenisation of the DLAV (30-48 hpf). As a polarised increase in 
Vegfa/Vegfr signalling is necessary to establish tip and stalk cells identity in the 
growing sprouts [6] and a local increase in VEGFA signalling is essential for the 
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establishment of stable connections between vascular sprouts in vivo and in vitro [30], 
we decided to investigate the  effect of a general reduction of this signalling pathway 
on the formation of a lumenised DLAV. For this purpose, we used the VEGFR2 inhibitor 
ZM323881, a tyrosine-kinase inhibitor that reduces Vegfa/Vegfr signalling [31], 
confirmed by down-regulation of p-ERK in FAC sorted endothelial cells from embryos 
treated with 50 nM ZM323881 and 1X tricaine from 30 to 48 hpf (Supplementary Figure 
3A-B). Consistent with its function, ZM323881-mediated down regulation of 
Vegfa/Vegfr signalling can be partially rescued with down-regulation of flt1 expression 
(Supplementary Figure 3E, F).  
  
Embryos treated with 1X tricaine and 100 or 150 nM ZM323881 from 30 to 48 hpf 
exhibited significant DLAV defects (Supplementary Figure 3C, D). In addition, even at 
the highest concentration not inducing any significant defect in DLAV establishment 
(50nM), we observed a strong defect in ISV lumenisation at 48 hpf (Figure 5D), 
suggesting that in addition to its importance in the ipsilateral anastomosis of aISVs and 
DLAV lumenisation, Vegfa/Vegfr signalling is important for the maintenance of aISV 
lumenisation.  
 
Vegfa/Vegfr signalling inhibition exacerbates svep1 loss-of-function DLAV 
phenotype in reduced flow conditions.  
 
As the DLAV phenotype in svep1 morphants can be rescued by an increase in 
Vegfa/Vegfr signalling (Figure 3), and because an expansion of tip cell numbers within 
aISVs does not appear to be causative for ipsilateral anastomosis defects (Figure 4), 
we investigated whether reducing  Vegfa/Vegfr signalling in svep1 morphants would 
exacerbate the DLAV defect observed under reduced flow conditions. 
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We took advantage of the variability in expressivity of the DLAV phenotype observed 
in different reporter lines (Supplementary Figure 1) to select one presenting with a 
limited DLAV phenotype when injected with svep1 morpholino and treated with 1X 
tricaine from 30 to 48 hpf. In this context, we find that concomitant treatment with 50 
nM ZM323881 results in a significant increase in the number of gaps in the DLAV 
(20.3%   21.8 versus 5.4%  9.3) and in a reduction of the number of lumenised DLAV 
segments (35.4  33.9 versus 76.9  24.9) (Figure 5A-C). Supporting this notion, we 
found that  treatment with the commonly used VEGFR signalling inhibitor SU5416 [3, 
12, 32, 33] also exacerbated the DLAV phenotype in svep1 morphants treated with 1X 
tricaine from 30 to 48 hpf (supplementary Figure 5A-C). 
 
In addition, we observed that svep1 morphants exhibited a mild but significant 
reduction in ISV lumenisation that was increased by treatment with 50 nM ZM323881 
under 1X tricaine conditions (26.9%  22.6 versus 80.3%  16.5)) (Figure 5E). 
Furthermore, we found that concomitant svep1 knockdown and Vegfa/Vegfr signalling 
inhibition lead to the emergence of embryos with a significant number of ISVs missing 
at 48 hpf (4.8%  9 versus 0.2  1.3%), following treatment with 50 nM ZM323881 and 
1X tricaine from 30 to 48 hpf (Figure 5F). Finally, we observed that in the context of 
Vegfr signalling inhibition, further reducing blood flow with increased tricaine 
concentration (2X) inhibition did not result in the same phenotypic severity as in svep1 
loss-of-function embryos treated with 1X tricaine. In embryos treated with 50nM 
ZM323881 and 2X tricaine from 30 to 48 hpf, 40.9%  21  of ISVs are lumenised 
(compared to 26.9%  22.6 in mild svep1 morphants treated with 1X tricaine and 50nM 
Zm323881) and 3.3%  5.8 of ISVs are missing at 48 hpf (compared to 26.9%  22.6 
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in mild svep1 morphants treated with 1X tricaine and 50nM Zm323881). This suggests 
that reduced function or loss of Svep1 and reduced blood flow both contribute to the 
emergence of a vascular phenotype in the context of Vegfa/Vegfr signalling inhibition 
(Figure 5G-J).  
 
Overall, these results suggest that Svep1 and Vegfa/Vegfr signalling appear to act 






The question of how vessels anastomose remains incompletely understood, given the 
complexities of endogenous and exogenous signals driving vascular remodelling and 
development in parallel and sometimes synergistic ways [1]. Careful and granular 
analysis of early stage angiogenesis has shed light on the temporal and morphological 
dynamics underlying this process [11, 34, 35]. Following the establishment of a stable 
connection between neighbouring tip cells, supported by the local deposition of 
adherens junctions proteins, such as VE-cadherin, F-actin and ZO-1 [35, 36], ISV 
connections become progressively lumenised. Lumenisation and stabilisation of ISV 
connections is thought to occur either through a flow-dependent transcellular hollowing 
of connecting tip cells (Type I anastomosis)[35, 37] or through a flow-independent 
process involving the coalescence of isolated luminal pockets into a single luminal 
space that will subsequently be perfused (Type II anastomosis)[34]. However, 
comparatively little is known about the molecular pathways leading to the formation 
and stabilisation of nascent anastomotic connections.  
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Here, we identified blood flow and Svep1 as regulators of vessel anastomosis in the 
developing zebrafish vasculature. Both appear to play a role in the stabilisation of 
nascent anastomotic connections between neighbouring vessels. Under reduced flow 
conditions, svep1 knockdown or loss-of-function scenarios result in reduced 
anastomosis of ipsilateral ISVs and defective formation of a lumenised DLAV at 48 hpf. 
We find that endothelial cells in svep1 morphants do not show significantly increased 
Vegfa/Vegfr signalling. This is surprising given the concomitant increase in Apelin 
positive cells in ISVs, as tip cells specification has been shown to correlate with higher 
level of Vegfa/Vegfr signaling [38]. We can speculate that the increase of Vegfa/Vegfr 
signalling in the trunk ISV of svep1 morphants is not ubiquitous across the endothelium 
and therefore cannot be detected with a global endothelial analysis. Alternatively, the 
increase and expansion of Apln levels in tip cells could be independent of increased 
ERK activity or Vegfr signalling. 
   
However, neither a Vegfa/Vegr signalling modulation nor the increased tip cell 
numbers  appear causative, as the DLAV defect can be rescued with flt1 knockdown 
and is exacerbated by Vegfa/Vegfr signalling inhibition. Interestingly, while further 
inhibition of blood flow speed below that exhibited in a context of svep1 loss-of-function 
and 1X tricaine treatment does similarly result in visible anastomosis defect in the 
DLAV region, these are not associated with a significant increase of Apelin positive 
cells in the trunk ISV, supporting our hypothesis that the expansion of the number of 
tip cells in aISVs per se is not the driver of anastomosis defects. 
 
The results about the role of Vegfa/Vegfr signalling in mediating vessel anastomosis 
in the zebrafish trunk appear at first sight hard to reconcile. However, previous work 
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on the role of VEGFR2 signalling in anastomosis allow us to speculate on the molecular 
mechanisms at play here.  
 
In the mouse retina, Nesmith and colleagues have shown that endothelial cells 
presenting with reduced Flt1 expression were more likely to form stable connections 
with approaching sprouts [30]. They also clarified that it is reduced mFlt1 expression 
that influences the bias towards stable connections, suggesting a cell-autonomous 
regulation of tip cell anastomosis. Finally, they remarked that sprouts with reduced Flt1 
expression exhibit reduced exploratory transient connections with adjacent sprouts, 
proposing that this might lead to an increase in the number of suboptimal new vascular 
connections. We noticed a significant increase of vascular loops within ISVs, which 
can functionally be considered suboptimal or redundant for perfusion of tissues, in 
embryos with reduced svep1 and flt1 expression compared to flt1 knockdown alone. 
On its own, this result suggests that Svep1 role in vascular development might occur 
through the modulation of Flt1 activity in vivo. As the function of Flt1 in developmental 
angiogenesis appears strictly limited to its role as a decoy receptor for VEGFA [26, 
39], we can speculate that Svep1 might support/enhance Flt1 decoy ability. 
Alternatively, we can speculate that flt1 and svep1 loss-of-function both drive excess 
tip cell formation in an additive fashion, and that the DLAV rescue observed in embryos 
with both loss-of-function could potentially result from an increased tip cell activity, 
driven by Vegfa/Vegfr signalling increase. This hypothesis would reconcile with our 
observation that in the context of reduced blood flow, in which embryos present with 
DLAV formation defects without increase in tip cell numbers, Vegfa/Vegfr signalling 
increase results in a rescue of the DLAV phenotype without aberrant ISV connections.  
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However, under reduced flow conditions, while flt1 knockdown enhances the formation 
of stable connections between ipsilateral neighbouring sprouts, we find that svep1 
knockdown alone leads to a significant reduction in the stability of these connections. 
In addition, we find that inhibition of Vegfa/Vegfr signalling leads to a DLAV phenotype 
comparable to that observed in svep1 mutant and morphants, and that Vegfa/Vegfr 
inhibition in svep1 morphants leads to a strong increase of anastomosis defects. Taken 
together, these results suggest that any potential increase in Vegfa/Vegfr signalling 
following svep1 knockdown would be compensatory in nature and insufficient to 
stabilise new connections in the absence of flow.  
 
The importance of blood flow inhibition in the emergence of the DLAV phenotype might 
suggest a potential investigative avenue. In embryos with reduced blood flow and 
concomitant reduced Svep1 levels or reduced Vegfa/Vegfr signaling, we observed a 
significant reduction in ISV lumenisation. This suggest that in this context, a significant 
proportion of ISVs might initiate anastomosis through flow-independent pathways 
(Type II anastomosis). We can speculate that blood flow plays a positive role in the 
stabilization of type II anastomosis between neighboring ISVs, which would explain the 
DLAV formation defect observed in reduced (tricaine treatment) or abolished (tnnt2a 
morpholino) blood flow conditions. The significant increase in DLAV phenotype 
observed in svep1 loss-of-function and abolished flow conditions suggest a role of 
Svep1 in regulating vessel anastomosis specifically under reduced flow conditions.  
 
 
In addition, while blood flow reduction between 30 and 48 hpf is sufficient to induce 
anastomotic defects in the DLAV, this phenotype is significantly exacerbated with 
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concomitant treatment with Vegfr signalling inhibitors, supporting the idea that flow and 
Vegfa/Vegfr signaling act synergistically to support vessel anastomosis.   
 
Svep1(also known as Polydom) is a secreted ECM protein that has been reported to 
mediate cell to substrate adhesion in vitro, at leasr in part in an integrin 91-
dependent manner [13]. Although integrin 9 zebrafish mutants fail to display a 
vascular phenotype other than lymphatic valve formation [40], interaction with another 
member of the Integrin family could prove more relevant. For example, Integrin 1b 
appears to be important for the formation of the DLAV in zebrafish embryos [41]. Future 
efforts in identifying interaction partners for Svep1 will further enhance our 
understanding of the molecular pathways regulating vessel anastomosis. Imaging of 
the svep1 reporter line Tg(svep1: Gal4FF;UAS:GFP) at 48 hpf showed strong GFP 
expression in dorsal epithelial cells, above the neural tube, and in individual neurons 
of the neural tube in close proximity to the anastomotic bridges forming between 
adjacent ISVs. We can speculate that neuronal expression of Svep1 is what locally 
regulates vessel anastomosis, in a non-cell autonomous manner. In addition, Svep1 is 
a multi-domain protein, and the importance of individual domains could be functionally 
tested in reduced flow conditions, by the generation of zebrafish lines expressing 
selective truncated forms of Svep1. Finally, the significant differences observed in 
svep1 loss-of-function phenotype expressivity between zebrafish lines might offer an 
interesting avenue to decipher the compensatory mechanisms at play and reveal new 
molecular pathways interacting with Svep1 in the regulation of vessel anastomosis.  
 
Understanding the genetic regulation of phenotypic robustness in angiogenesis and its 
failure [42] promises crucial insights into the mechanisms causing breakdown of 
vascular  homeostasis in human disease.  
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Figure 1 - svep1 mutants and morphants zebrafish embryos exhibit vascular 
anastomosis defects.  
 
(A) Stills from time lapse movie of MO-CTL (5ng) and MO-svep1 (5ng) Tg(-
0.8flt1:RFP)hu3333; TgBAC(flt4:Citrine) embryos treated with 1X (0.014%) 
tricaine from 30 to 48 hpf. White asterisks indicate gaps in the DLAV.  
 
(B) Still from a time lapse movie of MO-CTL (5ng) Tg(-0.8flt1:RFP)hu3333; 
TgBAC(flt4:Citrine) embryo exhibiting a gap in the DLAV between two 
adjacent ISVs. Side view, dorsal side left.  
 
(C) Bilateral quantifications of the percentage of gaps in the DLAV at 48 hpf in 
svep1512 WT (n=5), heterozygous (n=18) and homozygous mutants (n=10) 
treated with 1X tricaine (0.014%) from 30 to 48 hpf (N=3).  
 
(D) Bilateral quantifications of the percentage of lumenised segments in the DLAV 
at 48 hpf in svep1512 WT (n=5), heterozygous (n=18) and homozygous 
mutants (n=10) treated with 1X tricaine (0.014%) from 30 to 48 hpf (N=3).  
 
(E) Bilateral quantifications of the percentage of gaps in the DLAV at 48 hpf in 
MO-CTL (5 ng) (n=20) and MO-svep1 (5ng) (n=36) embryos treated with 1X 
tricaine (0.014%) from 30 to 48 hpf (N=6).  
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(F) Bilateral quantifications of the percentage of lumenised segments in the DLAV 
at 48 hpf in MO-CTL (5 ng) (n=20) and MO-svep1 (5ng) (n=36) embryos 
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Figure 2 – svep1 loss-of-function sensitises angiogenic remodelling to reduced 
blood flow. 
 
(A) Bilateral quantifications of the percentage of gaps in the DLAV at 48 hpf in 
MO-CTL (5 ng) and MO-svep1 (5ng) embryos treated with 0X (n=14 MO-CTL, 
n=20 MO-svep1), 0.5X (0.007%) (n=16 MO-CTL, n=24 MO-svep1), 1X 
(0.014%) (n=22 MO-CTL, n=27 MO-svep1) or 2X (0.028%) (n=21 MO-CTL, 
n=27 MO-svep1) tricaine from 30 to 48 hpf (N=3).  
 
(B) Bilateral quantifications of the percentage of lumenised segments in the DLAV 
at 48 hpf in MO-CTL (5 ng) and MO-svep1 (5ng) embryos treated with 0X 
(n=14 MO-CTL, n=20 MO-svep1), 0.5X (0.007%) (n=16 MO-CTL, n=24 MO-
svep1), 1X (0.014%) (n=22 MO-CTL, n=27 MO-svep1) or 2X (0.028%) (n=21 
MO-CTL, n=27 MO-svep1) tricaine from 30 to 48 hpf (N=3).  
 
(C) Bilateral quantifications of the percentage of gaps in the DLAV at 48 hpf in 
MO-CTL (5 ng) (n=13), MO-gata1 (8ng) (n=12), MO-svep1 (5ng) (n=16) and 
MO-gata1 (8ng)/MO-svep1 (5ng) (n=25) embryos (N=3).  
 
(D) Bilateral quantifications of the percentage of lumenised segments in the DLAV 
at 48 hpf in MO-CTL (5 ng) (n=13), MO-gata1 (8ng) (n=12), MO-svep1 (5ng) 
(n=16) and MO-gata1 (8ng)/MO-svep1 (5ng) (n=25) embryos (N=3).  
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(E) Bilateral quantifications of the percentage of gaps in the DLAV at 48 hpf in 
MO-CTL (5 ng) (n=11), MO-tnnt2a (4ng) (n=12), MO-svep1 (5ng) (n=12) and 
MO-tnnt2a (4ng)/MO-svep1 (5ng) (n=21) embryos (N=3).  
 
(F) Bilateral quantifications of the percentage of lumenised segments in the DLAV 
at 48 hpf in MO-CTL (5 ng) (n=11), MO-tnnt2a (8ng) (n=12), MO-svep1 (5ng) 
(n=12) and MO-tnnt2a (4ng)/MO-svep1 (5ng) (n=21) embryos (N=3).  
 
(G) Maximum intensity projection of representative DLAV in MO-CTL (5 ng) 
(n=11), MO-tnnt2a (8ng) (n=12), MO-svep1 (5ng) (n=12) and MO-tnnt2a 
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Figure 3 - svep1 loss-of-function leads to a defect in tip/stalk cell specification 
in primary angiogenic sprouts.  
 
(A) Representative images of 48 hpf Tg(svep1:Gal4FF; UAS:eGFP); 
Tg(kdrl:mcherry-CAAX)y171 embryos with or without treatment with 1X 
(0.014%) tricaine from 30 to 48 hpf.  
 
(B) Quantification of average numbers of Tg(svep1:Gal4FF; UAS:eGFP) positive 
neurons in the neural tube area of 48 hpf embryos with or without treatment 
with 1X (0.014%) tricaine from 30 to 48 hpf. (N=3, n=15 controls, n=16 
treated).  
 
(C) Maximum intensity projection of a representative TgBAC(apln:eGFP)bns157, 
Tg(-0.8flt1:RFP)hu5333 MO-CTL (5ng) embryo. C’ shows the unprocessed 
maximum intensity projection, C’’ shows the GFP signal volume-masked by 
the RFP signal, to limit detection to the endothelium and C’’’ shows the 
resulting endothelial GFP signal only.  
 
(D) Maximum intensity projection of a representative TgBAC(apln:eGFP)bns157, 
Tg(-0.8flt1:RFP)hu5333 MO-CTL (5ng) embryo. D’ shows the unprocessed 
maximum intensity projection, D’’ shows the GFP signal volume-masked by 
the RFP signal, to limit detection to the endothelium and D’’’ shows the 
resulting endothelial GFP signal only.  
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(E) Maximum intensity projection of a MO-CTL (5ng) aISV at 48 hpf, highlighting 
the ventral and dorsal region used for further quantifications in (F) and (G).  
 
(F) Quantification of the percentage of aISVs with apln:eGFP positive endothelial 
cells in the (1) dorsal and (2) ventral region in 48 hpf MO-CTL (5ng) (n=10) 
and MO-svep1(5ng) (n=16) morphant embryos treated with 1X (0.014%) 
tricaine from 30 to 48 hpf (N=3).  
 
 
(G) Quantification of the percentage of aISVs with more than one apln:eGFP 
positive endothelial cells in 48 hpf MO-CTL (5ng) (n =10) and MO-svep1 (5ng) 
(n=16) morphant embryos treated with 1X (0.014%) tricaine from 30 to 48 hpf 
(N=3).  
 
(H) Representative image of p-ERK and ERK levels in FAC sorted endothelial 
cells from MO-CTL (5ng) and MO-svep1 (5ng) morphants at 48hpf, treated 
with 1X (0.014%) tricaine from 30 to 48 hpf (N=4).  
 
 
(I)  Quantification of p-ERK in FAC sorted endothelial cells of MO-CTL (5ng) and 
MO-svep1 (5ng) morphants at 48hpf, treated with 1X (0.014%) tricaine from 
30 to 48 hpf. Expression levels were normalised to pERK levels (N=4).  
 
(J) Quantification of the percentage of aISVs with apln:eGFP positive endothelial 
cells in the (1) dorsal and (2) ventral region in 48 hpf embryos treated with 1X 
(0.014%)(n=22) or 2X (0.028%)(n=24) tricaine from 30 to 48 hpf (N=3).  
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(K) Quantification of the percentage of aISVs with more than one apln:eGFP 
positive endothelial cells in 48 hpf embryos treated with 1X (0.014%)(n=22) or 
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Figure 4 – svep1 loss-of-function and knockdown are rescued by flt1 
knockdown.  
 
(A) Bilateral quantifications of the percentage of gaps in the DLAV at 48 hpf in 
controls and mutant svep1512-/- injected with MO-CTL (5ng) (n= 45 and n=27 
respectively) or MO-flt1 (1ng) (n=50 and n=12 respectively), and treated with 
1X tricaine (0.014%) from 30 to 48 hpf (N=3).  
 
(B) Bilateral quantifications of the percentage of gaps in the DLAV at 48 hpf in 
MO-CTL (5 ng) (n=9), MO-flt1 (1ng) (n=7), MO-svep1 (5ng) (n=14) and MO-
flt1 (1ng)/MO-svep1 (5ng) (n=25) embryos (N=3). 
 
(C) Bilateral quantifications of the percentage of lumenised segments in the DLAV 
at 48 hpf in controls and mutant svep1512-/- injected with MO-CTL (5ng) (n= 45 
and n=27 respectively) or MO-flt1 (1ng) (n=50 and n=12 respectively),and 
treated with 1X tricaine (0.014%) from 30 to 48 hpf (N=3).   
 
(D) Bilateral quantifications of the percentage of lumenised segments in the DLAV 
at 48 hpf in MO-CTL (5 ng) (n=9), MO-flt1 (1ng) (n=7), MO-svep1 (5ng) (n=14) 
and MO-flt1 (1ng)/MO-svep1 (5ng) (n=25) embryos, treated with 1X tricaine 
(0.014%) from 30 to 48 hpf (N=3). 
 
(E) Bilateral quantifications of the percentage of aISV loops at 48 hpf in MO-CTL 
(5 ng) (n=11), MO-flt1 (1ng) (n=14), MO-svep1 (5ng) (n=11) and MO-flt1 
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(1ng)/MO-svep1 (5ng) (n=20) embryos treated with 1X tricaine (0.014%) from 
30 to 48 hpf (N=3). 
 
(F) Representative image of an arterial aISV loop in MO-svep1(5ng)/MO-flt1(1ng) 
Tg(-0.8flt1:RFP)hu3333 embryos at 48 hpf, treated with 1X(0.014%) tricaine from 
30 to 48 hpf. Tg(-0.8flt1:RFP)hu333 
 
(G) Quantification of number of nucleus per loop area (see figure 4F) at 48 hpf in 
MO-svep1(5ng)/MO-flt1(1ng) embryos at 48 hpf, treated with 1X (0.014%) 
tricaine from 30 to 48 hpf (n=34 loops counted. 2, 19, 9 and 4 loops had 1, 2, 3 
or 4 nucleus per loop area, respectively). 20/34 loops were lumenised) (N=3) 
 
(H) Representative image of an aISV to aISV connection in the region of the 
horizontal myoseptum at 48 hpf in in MO-svep1(5ng)/MO-flt1(1ng) Tg(-
0.8flt1:RFP)hu3333 embryos at 48 hpf, treated with 1X (0.014%) tricaine from 30 
to 48 hpf. (n=20 fish, 26 connections visible out of 280 somites, 8/26 
connections were lumenised, N=3).  
 
(I) Maximum intensity projection of a representative TgBAC(apln:eGFP)bns157, 
Tg(-0.8flt1:RFP)hu5333 morphant embryos at 48 hpf. The panels show the GFP 
signal volume-masked by the RFP signal, to limit detection to the endothelium 
in MO-CTL (5ng), MO-flt1 (1ng), MO-svep1 (5ng) and MO-svep1 (5ng) /MO-
flt1 (1ng) embryos treated with 1X (0.014%) tricaine from 30 to 48 hpf.  
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(J) Maximum intensity projection of a MO-svep1 (5ng)/MO-flt1 (1ng) aISV at 48 
hpf, highlighting the ventral and dorsal region used for further quantifications in 
(K).  
 
(K) Quantification of the percentage of aISVs with apln:eGFP positive endothelial 
cells in the (1) dorsal and (2) ventral region in 48 hpf MO-CTL (5ng) (n=12), 
MO-flt1 (1ng) (n=14), MO-svep1 (5ng)(n=12) and MO-svep1(5ng)/MO-flt1 
(1ng) (n=20) morphant embryos treated with 1X (0.014%) tricaine from 30 to 
48 hpf (N=3).  
 
(L) Quantification of the percentage of aISVs with more than one apln:eGFP 
positive endothelial cells in 48 hpf MO-CTL (5ng) (n=12),MO-flt1 (1ng) (n=14), 
MO-svep1 (5ng)(n=12) and MO-svep1 (5ng)/MO-flt1 (1ng) (n=20) morphant 
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Figure 5 – Vegfa/Vegfr signalling is necessary for ISV lumenisation maintenance 
and DLAV formation 
 
(A) Maximum intensity projections at 48 hpf of the trunk of MO-CTL (5ng) and 
MO-svep1 (5ng), Tg(fli1a:eGFP)y7 embryos, treated with 1X (0.014%) tricaine, 
with or without 50ng ZM32881.  
 
(B) Bilateral quantifications of the percentage of gaps in the DLAV at 48 hpf in 
MO-CTL (5 ng) (n=29 (0nM ZM32881), n=28 (50nM ZM32881)) MO-svep1 
(5ng) (n=29 (0 nM ZM32881), n=26 (50nM ZM32881)) embryos treated with 
1X (0.014%) tricaine and 0 or 50 nM ZM32881 from 30 to 48 hpf, (N=3). 
 
(C) Bilateral quantifications of the percentage of lumenised segments in the DLAV 
at 48 hpf in MO-CTL (5 ng) (n=29 (0nM ZM32881), n=28 (50nM ZM32881)) 
MO-svep1 (5ng) (n=29 (0 nM ZM32881), n=26 (50nM ZM32881)) embryos 
treated with 1X (0.014%) tricaine and 0 or 50 nM ZM32881 from 30 to 48 hpf 
(N=3). 
 
(D) Representative images of missing ISVs, fully lumenised ISV and not fully 
lumenised ISV at 48 hpf. Quantifications of these phenotypes are presented in 
(E) and (F).  
 
(E) Bilateral quantifications of the percentage of missing ISVs in the trunk of 48 
hpf  MO-CTL (5 ng) (n=29 (0nM ZM32881), n=28 (50nM ZM32881)) MO-
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svep1 (5ng) (n=29 (0 nM ZM32881), n=26 (50nM ZM32881)) embryos treated 
with 1X (0.014%) tricaine and 0 or 50 nM ZM32881 from 30 to 48 hpf (N=3). 
 
(F) Bilateral quantifications of the percentage of ISVs lumenised dorsally to 
ventrally in the trunk of 48 hpf  MO-CTL (5 ng) (n=29 (0nM ZM32881), n=28 
(50nM ZM32881)) MO-svep1 (5ng) (n=29 (0 nM ZM32881), n=26 (50nM 
ZM32881)) embryos treated with 1X (0.014%) tricaine and 0 or 50 nM 
ZM32881 from 30 to 48 hpf (N=3). 
 
(G) Bilateral quantifications of the percentage of gaps in the DLAV at 48 hpf in 
embryos treated with 2X (0.028%) tricaine and 0 (n=22) or 50 nM (n=21) 
ZM32881 from 30 to 48 hpf, (N=3). 
 
(H) Bilateral quantifications of the percentage of lumenised segments in the DLAV 
at 48 hpf in embryos treated with 2X (0.028%) tricaine and 0 (n=22) or 50 nM 
(n=21) ZM32881 from 30 to 48 hpf, (N=3) 
 
(I) Bilateral quantifications of the percentage of missing ISVs in the trunk of 48 
hpf in embryos treated with 2X (0.028%) tricaine and 50 nM (n=21) ZM32881 
from 30 to 48 hpf, (N=3). 
 
(J) Bilateral quantifications of the percentage of ISVs lumenised dorsally to 
ventrally in the trunk of 48 hpf in embryos treated with 2X (0.028%) tricaine 
and 50 nM (n=21) ZM32881 from 30 to 48 hpf, (N=3). 
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